Lobbyists have a better understanding of the parliament's importance than most members of the public. There are thousands of them in Brussels.
These two visitors are from a Finnish pharmaceuticals company. They told me about their concern that new legislation could classify drugs as "generic" too soon. It is in their interest for drugs to remain branded as long as possible.
Generic drugs are good news for patients, because they are cheaper. But companies also need to be rewarded for creativity, or they will stop inventing new treatments.